Susan Funk, NP
Acute Care · Greenville, SCNPI 1033114087
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Incyte Corporation at 34.8% of the total. Reporting peaked in 2022 at $4,994 and has fallen 78.4% since, to $1,079 in 2025. Among acute care clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $134.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$4K
- Janssen Scientific Affairs, LLC$2K
- Sanofi$1K
- CTI Biopharma Corp.$700
- AstraZeneca$456
- Johnson & Johnson$354
- plus $2K from 22 others
What the payments were for
- Consulting fees$5,95755%
- Speaking & faculty fees$7006%
- Food & beverage$3,87135%
- Education$3864%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 10 | $3,794 |
| Janssen Scientific Affairs, LLC | 10 | $1,962 |
| Sanofi | 2 | $1,424 |
| CTI Biopharma Corp. | 1 | $700 |
| AstraZeneca(2 entities) | 4 | $456 |
| Johnson & Johnson | 4 | $354 |
| Beigene USA, Inc. | 4 | $348 |
| E.r. Squibb & Sons, L.L.C. | 3 | $302 |
| Syndax Pharmaceuticals, Inc. | 3 | $206 |
| Astellas Pharma US Inc | 10 | $195 |
| Stemline Therapeutics Inc. | 2 | $146 |
| Adaptive Biotechnologies Corporation | 2 | $143 |
| Genmab U.S., Inc. | 1 | $122 |
| Amgen | 1 | $103 |
| AbbVie | 4 | $102 |
| Genentech, Inc. | 1 | $100 |
| Gilead | 1 | $87 |
| Novartis | 3 | $72 |
| Bristol Myers Squibb | 3 | $55 |
| GSK | 2 | $50 |
| Blueprint Medicines Corporation | 1 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Karyopharm Therapeutics Inc. | 2 | $25 |
| Merck | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| ADC Therapeutics America, Inc. | 1 | $16 |
| Seagen Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,913 in reported general payments places this provider in the 95th percentile of 339 acute care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 15 | $263,504 |
| Posaconazole | 26 | $38,984 |
| Atovaquone | 35 | $25,673 |
| ValacyclovirValacyclovir Hcl | 93 | $2,777 |
| Ursodiol | 20 | $1,686 |
| Fluconazole | 29 | $1,379 |
| Potassium Chloride | 43 | $646 |
| Ondansetron Hcl | 31 | $425 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 65 | $414 |
| Pantoprazole Sodium | 28 | $359 |
| Penicillin V Potassium | 22 | $270 |
| Acyclovir | 16 | $199 |
| Levofloxacin | 33 | $140 |
| Olanzapine | 11 | $136 |
| Folic Acid | 18 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $3,794 | $263,50415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 acute care providers in South Carolina.
Other acute care in Greenville
- Heather BowersGreenville$94K
- Sarah MatthewsGreenville$28K
- Jeffrey CobbGreenville$8K
- Jamez FletcherGreenville$7K
- Serena KocourekGreenville$7K
- Taylor NewtonGreenville$6K
- Cheryl MartinezGreenville$6K
- Stephanie RodriguezGreenville$6K
- Lucretia MyersGreenville$5K
- Jessica SentellGreenville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.